In last trading session, Inovio Pharmaceuticals Inc (NASDAQ:INO) saw 0.62 million shares changing hands with its beta currently measuring 0.89. Company’s recent per share price level of $2.09 trading at $0.0 or 0.00% at ring of the bell on the day assigns it a market valuation of $75.45M. That closing price of INO’s stock is at a discount of -605.74% from its 52-week high price of $14.75 and is indicating a premium of 16.75% from its 52-week low price of $1.74. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.83 million shares which gives us an average trading volume of 994.45K if we extend that period to 3-months.
For Inovio Pharmaceuticals Inc (INO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.83 in the current quarter.
Inovio Pharmaceuticals Inc (NASDAQ:INO) trade information
Inovio Pharmaceuticals Inc’s shares saw a change of 14.21% in year-to-date performance and have moved -4.13% in past 5-day. Inovio Pharmaceuticals Inc (NASDAQ:INO) showed a performance of 17.42% in past 30-days. Number of shares sold short was 3.5 million shares which calculate 11.22 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 8 to the stock, which implies a rise of 73.88% to its current value. Analysts have been projecting 8 as a low price target for the stock while placing it at a high target of 8. It follows that stock’s current price would drop -282.78% in reaching the projected high whereas dropping to the targeted low would mean a loss of -282.78% for stock’s current value.
Inovio Pharmaceuticals Inc (INO) estimates and forecasts
Statistics highlight that Inovio Pharmaceuticals Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -80.39% of value to its shares in past 6 months, showing an annual growth rate of 27.59% while that of industry is 16.00. Apart from that, the company came raising its revenue forecast for fiscal year 2025. This year revenue growth is estimated to fall -84.92% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 25k for the same. And 1 analysts are in estimates of company making revenue of 100k in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 13.49% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 30.90% while estimates for its earnings growth in next 5 years are of 29.92%.
Inovio Pharmaceuticals Inc (NASDAQ:INO)’s Major holders
Insiders are in possession of 0.85% of company’s total shares while institution are holding 33.51 percent of that, with stock having share float percentage of 33.80%. Investors also watch the number of corporate investors in a company very closely, which is 33.51% institutions for Inovio Pharmaceuticals Inc that are currently holding shares of the company.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 818.82 shares of worth $1.71 million or 3.14% of the total outstanding shares. The later fund manager was in possession of 738.85 shares on Nov 30, 2024 , making its stake of worth around $1.54 million in the company or a holder of 2.83% of company’s stock.
